(Q39390362)

11 September 2017

Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy (English)

1 reference

randomized controlled trial

11 September 2017

0 references

1 reference

based on heuristic

inferred from title

Anesthesiology and pain medicine

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

11 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

11 March 2024

author name string

Dwight Moulin

2

1 reference

11 September 2017

Judith Watt-Watson

3

1 reference

11 September 2017

Allan Gordon

4

1 reference

11 September 2017

John Eisenhoffer

5

1 reference

11 September 2017

C. Peter N. Watson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14499422

11 March 2024

language of work or name

English

0 references

publication date

1 September 2003

1 reference

full work available at URL

11 September 2017

https://journals.lww.com/10.1016/S0304-3959(03)00160-X

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

11 March 2024

1 reference

11 September 2017

105

1 reference

11 September 2017

71-78

1 reference

11 September 2017

1-2

1 reference

Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology

11 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

11 March 2024

3

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Peripheral diabetic neuropathy: current concepts in treatment

11 March 2024

4

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies

11 March 2024

6

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Prevention and treatment of the complications of diabetes mellitus

11 March 2024

7

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review

11 March 2024

8

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

The number needed to treat: a clinically useful measure of treatment effect

11 March 2024

9

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Prolonged treatment with transdermal fentanyl in neuropathic pain

11 March 2024

10

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale

11 March 2024

12

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain

11 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy

11 March 2024

15

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood

11 March 2024

18

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial

11 March 2024

19

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy

11 March 2024

20

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

11 March 2024

21

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

A systematic review of antidepressants in neuropathic pain

11 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics

11 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Chronic opioid therapy as alternative treatment for post-herpetic neuralgia

11 March 2024

24

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Controversies in the long-term management of analgesic therapy in patients with advanced cancer

11 March 2024

26

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Addiction Rare in Patients Treated with Narcotics

11 March 2024

27

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study

11 March 2024

28

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.

11 March 2024

29

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia

11 March 2024

30

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Gabapentin for the Treatment of Postherpetic Neuralgia: A Randomized Controlled Trial

11 March 2024

31

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol�): Double blind crossover trial

11 March 2024

32

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Phenytoin in the treatment of diabetic symmetrical polyneuropathy

11 March 2024

33

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

The Landscape and Lexicon of Blinding in Randomized Trials

11 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.

11 March 2024

35

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Imipramine treatment in diabetic neuropathy: relief of subjective symptoms without changes in peripheral and autonomic nerve function

11 March 2024

36

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial.

11 March 2024

37

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

11 March 2024

Diabetic neuropathies

39

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia

11 March 2024

40

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology

11 March 2024

44

1 reference

https://api.crossref.org/works/10.1016/S0304-3959(03)00160-X

11 March 2024

Identifiers

1 reference

11 September 2017

1 reference